摘要
目的探讨补脾强力复方对胸腺切除术后MG的有效性和安全性。方法回顾性分析就诊于我院的MG并胸腺切除术患者31例,其中对照组为于外院手术者16例,手术前后根据个体情况不同分别予以(溴吡斯的明+泼尼松/甲泼尼龙/地塞米松等)治疗,治疗组(补脾强力复方组)为于我院手术者15例,治疗在前者基础之上于手术前后分别加用补脾强力复方,观察比较两组治疗前后MG临床绝对评分、临床相对记分、QMG评分。结果两组一般情况比较,差异无统计学意义;治疗后两组组内手术前后MG临床绝对评分、相对评分、QMG评分比较均存在统计学差异,表明胸腺切除术后MG症状改善情况在统计学意义;组间在MG胸腺切除术后MG临床绝对评分、相对评分、QMG评分差异有统计学意义,显示治疗组疗效更有优势。结论胸腺切除术是治疗MG的重要治疗方法,治疗组和对照组均能显著改善MG胸腺切除术后重症肌无力患者的临床症状,而治疗组(补脾强力复方组)优于单纯西药治疗胸腺切除术后MG的疗效,且无肌无力危象发生,具有更为理想的有效性和安全性。
Objective To explore efficacy and safety of Bu Pi Qiang Li Fu Fang to MG after thymectomy. Methods Restrospectie analysis was perpimed on 31 patrents with MG and thy mectorny,which irsited our hospital,including control group of 16 cases which did surgery in other hospitals.（ Pyridostigmine Bromide Tablets ＋ Prednisone Acetate / Methylprednisolone Acetate / Dexamethasone Sodium Phosphate,etc.） were given to them according to individual circumstance before and after operation. 15 patients in treatrnent group（ Bu Pi Qiang Li Fu Fang group） did thymectomy in our hospital,which treatment was based on the former and added with Bu Pi Qiang Li Fu Fang before and after operation. compare MG clinical absolute score and clinical relative score,QMG score of two groups before and after treatment. Results There was no statistically significant difference of general condition between two groups. MG clinical absolute scores,relative score and QMG score in two groups were statistical different before and after operation,which indicates that the MG symptoms have been improved obviously after thymectomy. Difference between the two groups of clinical absolute score,relative score and QMG score were statistically significant after thymectomy,and treatment group curative effect is better. Conclusion Thymectomy is an important treatment of MG. Clinical symptoms of both treatment group and control group were significantly improved after thymectomy. And curative effect of treatment group（ Bu Pi Qiang Li Fu Fang group） is superior to western medicine treatment after thymectomy,which without myasthenia crisis,and has better efficacy and safety.
出处
《时珍国医国药》
CAS
CSCD
北大核心
2016年第2期383-385,共3页
Lishizhen Medicine and Materia Medica Research
基金
国家自然科学基金(No.81360605)
